Tadahiro Shoji

21PUBLICATIONS
61CO-AUTHORS
Molecular targetsPacific Peoples medicine and treatmentsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Sep 26, 2026
Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology.

|Aug 07, 2026
Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study.

|May 13, 2026
Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction.

|Feb 13, 2026
Clinical and prognostic insights into Trousseau's syndrome in gynecologic malignancies: a multicenter study.

Hemian Zhang, Masayuki Futagami, Rie Miura

|Jan 22, 2026
Peripheral blood lymphocyte and eosinophil dynamics with chemotherapy and pembrolizumab in cervical cancer.

Sho Sato, Masahiro Kagabu, Ami Jo

|Jan 17, 2026
Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment.

Eriko Takatori, Tadahiro Shoji, Ami Jo

Pageof 4

Frequent Collaborators

10 joint publications

Tsukasa Baba

9 joint publications

Masahiro Kagabu

4 joint publications

Takayuki Nagasawa

4 joint publications

Sho Sato